Abstract
Tobacco use will kill as many as 1 billion people in the 21st century unless its use is curtailed. Smoking cessation is associated with several health and personal benefits; however, smoking cessation is difficult because of the highly addictive nature of nicotine.
Successful smoking cessation strategies can generally be divided into two groups: nicotine replacement therapy (NRT) and behavioral modification. The National Cancer Institute in the US advocates the use of the ‘Ask-Assess-Advise-Assist-Arrange’ approach to strengthen the role of the healthcare provider in initiating and sustaining smoking cessation. The ‘stages of change’ model is also useful in tailoring the physician’s approach to smoking cessation to the patient’s attitude to this change.
There are several approved types of NRT. These include nicotine polacrilex gum, transdermal nicotine patches, nicotine lozenges, nicotine nasal sprays, nicotine inhalers, and nicotine lollipops. Nicotine polacrilex gum, nicotine transdermal patches, and nicotine lozenges are available both on prescription and over the counter. Nicotine nasal sprays and nicotine inhalers are available by prescription only, while nicotine lollipops are compounded by pharmacists. One of the drawbacks of these therapies is that they can be used in excess of recommended doses or durations of therapy. They are also all subject to the adverse effects of nicotine, which include dizziness, altered cardiac rhythms, nausea and vomiting, fatigue and muscle aches, and headache. Orally administered NRT is also associated with the additional adverse effects of sore throat, mouth sores, esophageal irritation, and stomach pain, while nicotine inhalers are associated with throat and airway irritation and coughing; nicotine nasal sprays are associated with a runny nose, sneezing, throat irritation, and coughing early in the course of treatment; and transdermal nicotine patches are associated with skin irritation.
More recently, other pharmacological treatments have been used for smoking cessation. Bupropion was developed as an antidepressant, but has been shown to reduce the desire to smoke. Bupropion may be used in combination with NRT and may also be helpful in reducing post-cessation weight gain. Varenicline is a specifically designed smoking cessation medication. It has been shown to greatly reduce both smoking withdrawal symptoms and the desire to smoke. However, varenicline has been associated with mood alteration that may be as severe as to include suicidality, gastrointestinal adverse effects, and sleep disturbances. Other pharmacological and non-pharmacological therapies have been used in smoking cessation, with variable effects.
Smoking cessation is difficult and ‘staying quit’ is even more so. Most individuals ‘quit’ more than once before they become tobacco free. Two major factors in this are the addictive nature of nicotine and post-cessation weight gain. Successful smoking cessation may require combinations of pharmacological therapies and behavioral modification. Therapies may need to be used in excess of recommendations. Tobacco smoking is a lethal addiction. No effort should be spared in achieving successful smoking cessation.
Similar content being viewed by others
References
Huber GL. Tobacco: its history, economics, and political influence. Sem Resp Med 1989; 10: 278–96
Huber GL, Johnson V, Pandina RJ. The environmental smoke social movement: impact on tobacco use and smoking cessation. Sem Resp Cin Care Med 1995; 16: 111–33
Huber GL. The economics of tobacco use. In: Bollinger CT, Fagerstrom KO, editors. The tobacco epidemic. Prog Resp Res 1997; 28: 12–63
WHO. WHO report on the global tobacco epidemic, 2008: the MPOWER package [online]. Available from URL: http://www.who.int/tobacco/mpower/en/index.html [Accessed 2008 Jul]
US Department of Health and Human Services, Centers for Disease Control and Prevention. 2004 Surgeon General’s report: the health consequences of smoking [online]. Available from URL: http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2004/index.htm [Accessed 2007 Oct 2]
US Department of Health and Human Services, Centers for Disease Control and Prevention. The health consequences of smoking: nicotine addiction. A report of the Surgeon General, 1988 [online]. Available from URL: http://profiles.nlm.nih.gov/NN/B/B/Z/D/_/nnbbzd.pdf [Accessed 2004 Oct]
US Department of Health and Human Services. Centers for Disease Control and Prevention. Reducing the consequences of smoking: 25 years of progress. A report of the Surgeon General, 1989 [online]. Available from URL: http://profiles.nlm.nih.gov/NN/B/B/X/S/_/nnbbxs.pdf [Accessed 2008 Jul]
US Department of Health and Human Services. Reducing tobacco use: a report of the Surgeon General [report no. publication no. (PHS) 87-8398]. Washington, DC: Department of Health and Human Services, 1986
Centers for Disease Control. Cigarette smoking among adults: United States, 2003. Atlanta (GA): Centers for Disease Control and Prevention. MMWR 2005; 54(20): 509–13 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5420a3.htm [Accessed 2007 Oct 2]
US Department of Health and Human Services. Centers for Disease Control and Prevention. The health benefits of smoking cessation: a report of the Surgeon General, 1990 [online]. Available from URL: http://profiles.nlm.nih.gov/NN/B/B/C/T/_/nnbbct.pdf [Accessed 2007 Oct 2]
Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3): CD000146
Huber GL, Byrne B, Allen TG, et al. The role of nicotine in smoking behavior. Sem Resp Crit Care Med 1995; 16: 134–54
Huber GL, Burke MA, Nett LM. Smoking cessation. Sem Resp Med 1986; 8: 147–57
American Cancer Society. Guide to quitting smoking [online]. Available from URL: http://www.cancer.org/docroot/PED/content/PED_10_13X_Guide_for_Quitting_Smoking.asp [Accessed 2008 Jul]
Glynn TJ, Manley MW, Pechacek TF. Physician-initiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res 1990; 339: 11–25
Ockeene JK, Kristeller J, Goldberg R, et al. Increasing the efficacy of physiciandelivered smoking interventions: a randomized clinical trial. J Gen Intern Med 1991; 6: 1–8
Prokhorov AV, Hudmon KS, Gritz ER. Promoting smoking cessation among cancer patients: a behavioral model. Oncology 1997; 11: 1807–14
Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: quick reference guide for clinicians. Rockville (MD): US Department of Health and Human Services, 2000
American Cancer Society. The American Cancer Society Quitline® [online]. Available from URL: http://www.cancer.org/docroot/PED/content/PED_10_5_lx_Quitline_Partnerships.asp [Accessed 2008 Nov 21]
American Lung Association [online]. Available from URL: http://www.lungusa.org/ [Accessed 2008 Nov 21]
American Heart Association [online]. Available from URL: http://www.americanheart.org [Accessed 2008 Nov 21]
Centers for Disease Control and Prevention [online]. Available from URL: http://www.cdc.gov/ [Accessed 2008 Nov 21]
American Cancer Society [online]. Available from URL: http://www.cancer.org [Accessed 2008 Nov 21]
Nicotine Anonymous [online]. Available from URL: http://www.nicotineanonymous.org/ [Accessed 2008 Nov 21]
Smokefree.gov [online]. Available from URL: http://www.smokefree.gov/ [Accessed 2008 Nov 21]
Huber GL, Mahajan VK, Rubin A-HE. Theoretical and experimentally quantifiable determinants of tobacco smoking behavior for the development of successful smoking cessation strategies. Cancer Detect Prev 1990; 14: 505–14
Pandina RJ, Huber GL. Tobacco, nicotine, and the question of addiction: what to do about a difficult problem. Sem Resp Med 1990; 11: 50–68
Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med 2000; 9: 270–81
Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994; 308: 21–6
Fagerstron KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res 2002; 4 Suppl. 2: 573–9
Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72–6
Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007; 9(3): 315–27
Underner M, Paquereau J, Meurice JC. Cigarette smoking and sleep disturbances. Rev Mal Respir 2006; 23 Suppl. 3: 67–77
Joseph AM, Fu SS. Smoking cessation for patients with cardiovascular disease: what is the best approach? Am J Cardiovasc Drugs 2003; 3: 339–49
Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003; 45: 429–41
Batra A, Klinger K, Landfeldt B, et al. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2005; 78: 689–96
Tønnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counseling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addictive Behaviors 1988; 13(1): 17–27
Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003; 5: 181–7
Zevin S, Jacob 3rd P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998; 64: 87–95
Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled clinical trials. JAMA 1991; 266: 3133–8
Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31–42
Tønnesen P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311–5
Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7
Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psycho 2006; 74: 276–85
Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162(11): 1267–76
Shiffman S. Nicotine lozenge efficacy in light smokers. Drug Alcohol Depend 2007; 77: 311–4
Sutherland G, Stapleton JA, Russell MA, et al. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–9
Huber GL. Physical, chemical, and biological properties of the tobacco cigarette and other tobacco products. Sem Resp Med 1989; 10: 278–96
Bolliger CT, Zellweger JP, Danielson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomized clinical trial and safety. BMJ 2000; 321: 329–33
Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–71
Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. Arch Intern Med 1997; 157: 1721–8
Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007; 16: 22–8
Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco. Cancer Causes Control 2005; 6: 347–58
Cogliano V, Straif K, Baan R, et al. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004; 5(12): 708
Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD000124
Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91
Huber GL, Shafer DR, Pandina RJ. Tobacco smoking, smoking cessation, nutrition, and metabolism. Sem Resp Med 1990; 11: 69–86
Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotine receptor partial agonist: results from a 7-week, randomized, placebo-and-buproprion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561–8
Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 71–7
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release buproprion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56–63
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release buproprion and placebo for smoking cessation: a randomized clinical trial. JAMA 2006; 296: 47–55
Bachynsky N. The use of anticholinergic drugs for smoking cessation: a pilot study. Int J Addict 1986; 21: 789–805
Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first line aid to help smokers quit? Results from a systemic review and meta-analysis. Addiction 2005; 100: 317–26
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 1997; (3): CD000031
Hilleman DE, Mohiuddin MG, Lucas Jr BD. Randomized, controlled trial of transdermal Clonidine for smoking cessation. Ann Pharmacotherapy 1993; 27: 1025–8
Abbot NC, Stead LF, White AR, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD001008
White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2006; (1): CD000009
Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med 2006; 145: 845–56
Nett LM, Obrigewitch R. Nicotine dependency treatment: a role for the nurse practitioner. Nurse Pract For 1993; 4: 37–42
Petty TL, Nett LM. A medical approach to nicotine addiction treatment. Cleve Clin J Med 1993; 60: 254–8
Shiffman S, Ferguson SG, Gwaltney CJ, et al. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology 2006; 184: 637–44
Lerman C, Patterson F, Berrettini W. Treating nicotine dependence: state of the science and new directions. J Clin Oncol 2005; 23: 311–23
Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. Cancer J Clin 2005; 55: 281–99
Medioni J, Berlin I, Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modeling approach. Addiction 2005; 100: 247–54
Huber GL, Pandina RJ. Appetitive functions and dysfunctions: tobacco. Sem Rep Med 1990; 11: 1–4
Ferrara CM, Kumar M, Nicklas B, et al. Weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes 2001; 25: 1322–6
Eisenberg D, Quinn BC. Estimating the effect of smoking cessation on weight gain: an instrumental variable approach. Health Serv Res 2006; 41: 2255–66
Filozof C, Fernández Pinilla MC, Fernández-Cruz A. Smoking cessation and weight gain. Obes Rev 2004; 5(2): 95–103
Huber GH, Mahajan VK. Women, smoking cessation, and obesity: a collision course in search of a solution. RT 1996; 9: 89–93
Acknowledgments
No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huber, G.L., Mahajan, V.K. Successful Smoking Cessation. Dis-Manage-Health-Outcomes 16, 335–343 (2008). https://doi.org/10.2165/0115677-200816050-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/0115677-200816050-00010